# MyoKardia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/myokardia

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Total disclosed funding: $94M
- Latest round: Series B (Apr 20, 2015)
- Investors on record: 7

## About

Established in 2012 and based in California, US, MyoKardia, Inc. operates as a biopharmaceutical company that focuses on the research and development of therapies for the treatment of cardiomyopathy disease and other heart failure-related diseases.

## Funding rounds

- Series B, Apr 20, 2015, $46M — Casdin Capital, Sanofi, Cowen Inc., Cormorant Asset Management, Perceptive Advisors, BridgeBio
- Series A, Aug 18, 2014, $9.9M — Third Rock Ventures
- Series A, Sep 20, 2012, $38M — Third Rock Ventures

## Investors

- Third Rock Ventures (https://capitalatlas.ai/funds/third-rock-ventures) — Series A
- Casdin Capital (https://capitalatlas.ai/funds/casdin-capital) — Series B
- Sanofi — Series B
- Cowen Inc. — Series B
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series B
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series B
- BridgeBio — Series B